Determining post-shock treatment based on heart viability

Patent metadata

Field	Value
Publication number	US-12070613-B2
Application number	US-202017093531-A
Country	US
Kind code	B2
Filing date	Nov 9, 2020
Priority date	May 30, 2013
Publication date	Aug 27, 2024
Grant date	Aug 27, 2024

Abstract

A medical device can include a housing, an energy storage module within the housing to store an electrical charge, and a defibrillation port to guide via electrodes the stored electrical charge to a person in need of medical assistance. The medical device can also include a processor to analyze patient physiological signal(s) that indicate heart viability. Positive measures of heart viability measures can qualify the patient for a customized treatment paradigm.

First claim

What is claimed is:

1. A medical device, comprising:
a processor configured to:
identify a ventricular fibrillation (VF) cardiac event by analyzing an ECG signal of a patient;
generate a viability index by analyzing the VF cardiac event and a patient physiological parameter;
determine a classification of the VF cardiac event as a first VF type or a second VF type by analyzing the viability index;
in response to determining the classification of the VF cardiac event, determine a post-defibrillation shock treatment for the patient; and
output an instruction to perform the post-defibrillation shock treatment following delivery of a defibrillation shock to the patient.

2. The medical device of claim 1 , wherein the patient physiological parameter comprises an ECG signal indicative of coarse VF or fine VF.

3. The medical device of claim 2 , wherein the ECG signal indicates coarse VF and the post-defibrillation shock treatment comprises a post-defibrillation shock pause following the defibrillation shock and before CPR chest compressions begin.

4. The medical device of claim 2 , wherein the ECG signal indicates coarse VF and the post-defibrillation shock treatment comprises trans-thoracic pacing.

5. The medical device of claim 2 , wherein the ECG signal indicates fine VF and the post-defibrillation shock treatment comprises an immediate application of CPR chest compressions following the defibrillation shock.

6. The medical device of claim 1 , wherein the patient physiological parameter comprises a CO 2 measurement, a blood flow measurement, or a pulse detection measurement.

7. The medical device of claim 1 , wherein the processor is further configured to analyze the ECG signal within 10 seconds following the delivery of the defibrillation shock to the patient.

8. The medical device of claim 1 , wherein the processor is further configured to output the instruction by causing an output device to output a visual or audio instruction to activate the post-shock treatment in response to the delivery of the defibrillation shock.

9. The medical device of claim 1 , wherein the medical device further comprises electrodes coupled to the patient, the electrodes being configured to output the ECG signal to the processor.

10. The medical device of claim 1 , wherein the processor is configured to generate the classification of the VF cardiac event as the first VF type or the second VF type by comparing an amplitude of the ECG signal to a threshold.

11. The medical device of claim 1 , wherein the processor is configured to determine the classification of the VF cardiac event as the first VF type or the second VF type by performing an amplitude spectral analysis (AMSA) technique.

12. A medical device, comprising:
a discharge circuit configured to output a defibrillation shock to a patient's heart;
a measurement circuit configured to obtain an ECG signal of the patient's heart;
a processor configured to:
identify the presence of a ventricular fibrillation (VF) cardiac event in the patient's heart by analyzing the ECG signal of the patient's heart;
identify a viability of the heart of the patient in response to the defibrillation shock by analyzing a quality of the ECG signal;
classify the VF cardiac event as a coarse VF type by analyzing the viability of the heart of the patient;
determine a post-shock treatment for the patient based at least partly on the classification of the VF cardiac event as the coarse VF type; and
output an instruction to activate a post-shock treatment in response to a delivery of a defibrillation shock, the post-shock delivery comprising an instruction to forego administration of chest compressions immediately after delivery of the defibrillation shock.

13. The medical device of claim 12 , wherein the processor is further configured to classify the VF cardiac event as the coarse VF type further by:
identifying an amplitude of the ECG signal; and
comparing the amplitude of the ECG signal to a threshold.

14. A medical device, comprising:
a processor configured to:
determine that a heart of a patient has experienced a ventricular fibrillation (VF) event by analyzing an ECG signal indicative of electrical activity in the heart of the patient;
determine that the VF event is a coarse VF type cardiac event by analyzing a feature of the ECG signal; and
in response to determining that the VF event is the coarse VF type cardiac event, determine a treatment for the patient, the treatment comprising an instruction to pause chest compressions immediately after administration of a defibrillation shock; and

an output configured to generate an instruction to activate the treatment in response to delivery of the defibrillation shock to the patient.

15. The device of claim 14 , wherein the medical device is a monitor-defibrillator, a mechanical chest compression machine, or an external device electronically coupled to both of the monitor-defibrillator and the mechanical chest compression machine.

16. The device of claim 14 , wherein the processor is configured to determine that the VF cardiac event is the coarse VF type cardiac event by comparing an amplitude of the ECG signal to a threshold.

17. The device of claim 16 , wherein the processor is further configured to identify a viability of the heart in response to the defibrillation shock by analyzing a quality of the ECG signal and to determine that the VF cardiac event is the coarse VF type cardiac event by analyzing the viability.

18. The device of claim 17 , wherein the processor is configured to analyze the quality of the ECG signal by performing an amplitude spectral analysis (AMSA) technique.

19. The medical device of claim 1 , wherein the first VF type comprises fine VF and the second VF type comprises coarse VF.

20. The medical device of claim 19 , wherein the processor is configured to generate the viability index by comparing the patient physiological parameter to a threshold.

Assignees

• Physio Control Inc

Inventors

• Sullivan Joseph L
• Chapman Fred

Classifications

• A61H2201/5007

  computer controlled · CPC title

• A61H2230/045

  used as a control parameter for the apparatus · CPC title

• A61H2201/5097

  wireless · CPC title

• A61H2201/5061

  Force sensors · CPC title

• A61H2201/5043

  Displays · CPC title